Implants with controlled drug delivery features and methods of using same

Abstract

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 62 / 004,824, filed May 29, 2014, and titled IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME, which is hereby incorporated by reference in its entirety and made a part of this specification for all that it discloses.BACKGROUND[0002]1. Field[0003]This disclosure relates to implantable intraocular drug delivery devices structured to provide targeted and / or controlled release of a drug to a desired intraocular target tissue and methods of using such devices for the treatment of ocular diseases and disorders. In certain embodiments, this disclosure relates to a treatment of increased intraocular pressure wherein aqueous humor is permitted to flow out of an anterior chamber of the eye through a surgically implanted pathway. In certain embodiments, this disclosure also relates particularly to a treatment of ocular disea...

AI Technical Summary

Benefits of technology

The patent describes an ocular implant that can treat both pharmaceutical and physical therapy for ocular conditions. The implant has a stent that provides a pathway for draining fluid from the eye and reducing intraocular pressure. The implant can also release a first drug to treat the condition, while reducing side effects associated with the treatment. Overall, the implant can limit treatment-related side-effects and provide better outcomes for patients.

Problems solved by technology

Numerous pathologies can compromise or entirely eliminate an individual's ability to perceive visual images, including trauma to the eye, infection, degeneration, vascular irregularities, and inflammatory problems.

Glaucoma causes pathological changes in the optic nerve, visible on the optic disk, and it causes corresponding visual field loss, which can result in blindness if untreated.

Many pathologies of the eye progress due to the difficulty in administering therapeutic agents to the eye in sufficient quantities and / or duration necessary to ameliorate symptoms of the pathology.

Due to this metabolism, systemic administration may require undesirably high concentrations of the drug to reach therapeutic levels at an ocular target site.

This can not only be impractical or expensive, but may also result in a higher incidence of side effects.

Topical administration is potentially limited by limited diffusion across the cornea, or dilution of a topically applied drug by tear-action.

Even those drugs that cross the cornea may be unacceptably depleted from the eye by the flow of ocular fluids and transfer into the general circulation.

Images